Used in targeted cancer therapies, particularly for tumors with the KRAS G12C mutation, such as non-small cell lung cancer. It works by selectively binding to the mutated K-Ras protein in its inactive state, preventing it from switching to its active form, thereby blocking downstream signaling pathways that drive cell proliferation and survival. This inhibition leads to reduced tumor growth and can induce tumor regression in preclinical models. Its high selectivity for the G12C mutant over wild-type KRAS minimizes off-target effects, making it a promising candidate for clinical development in precision oncology.